Systemic Lupus
13
1
1
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
15.4%
2 terminated out of 13 trials
75.0%
-11.5% vs benchmark
15%
2 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (13)
Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus
Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases
ASA Patterns for Prevention of Preeclampsia in SLE Pregnancies
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease
Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)
Serum Ceramides Level in Systemic Lupus Erythematosus (SLE) Patients as a Novel Marker for Renal Impairment
Immune Adsorption Role in Treatment of Resistant Lupus
Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases
Yellow Fever Vaccine in Patients With Rheumatic Diseases
Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE
SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis
Use of Social Media to Improve Medication Adherence in Adolescents and Young Adults With Systemic Lupus
Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)